STIM — Neuronetics Share Price
0.000.00%
Last trade - 00:00- $294.85m
- $335.63m
- $74.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.64 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.56% | ||
| Return on Equity | -141.23% | ||
| Operating Margin | -52.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 49.24 | 55.31 | 65.21 | 71.35 | 74.89 | 148.57 | 163.17 | 3.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Directors
- Keith Sullivan PRE (61)
- Stephen Furlong CFO (57)
- W. Andrew Macan SVP (48)
- Cory Anderson VPR
- Todd Cushman VBD
- John Bakewell IND (60)
- Robert Cascella IND (67)
- Sheryl Conley IND (61)
- Wilfred Jaeger IND (65)
- Glenn Muir IND (62)
- Megan Rosengarten IND
- Bruce Shook IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 3rd, 2001
- Public Since
- June 28th, 2018
- No. of Shareholders
- 56
- No. of Employees
- 716
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 65,814,512
- Address
- 3222 Phoenixville Pike, MALVERN, 19355
- Web
- https://neurostar.com/neuronetics/
- Phone
- +1 6106404202
- Contact
- Mark Klausner
- Auditors
- KPMG LLP
Upcoming Events for STIM
Q1 2025 Neuronetics Inc Earnings Release
Neuronetics Inc Annual Shareholders Meeting
Neuronetics Inc Annual Shareholders Meeting
Q2 2025 Neuronetics Inc Earnings Release
Similar to STIM
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the Neuronetics share price?
As of Today at 22:14 UTC, shares in Neuronetics are trading at $4.48. This share price information is delayed by 15 minutes.
How has the Neuronetics share price performed this year?
Shares in Neuronetics last closed at $4.48 and the price had moved by +27.27% over the past 365 days. In terms of relative price strength the Neuronetics share price has outperformed the S&P500 Index by +17.48% over the past year.
What are the analyst and broker recommendations for Neuronetics?
The overall consensus recommendation for Neuronetics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Neuronetics dividend yield?
Neuronetics does not currently pay a dividend.
Does Neuronetics pay a dividend?
Neuronetics does not currently pay a dividend.
When does Neuronetics next pay dividends?
Neuronetics does not currently pay a dividend.
How do I buy Neuronetics shares?
To buy shares in Neuronetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neuronetics?
As of the previous close price of $4.48, shares in Neuronetics had a market capitalisation of $294.85m.
Where are Neuronetics shares listed?
Here are the trading details for Neuronetics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: STIM
What kind of share is Neuronetics?
Based on an overall assessment of its quality, value and momentum Neuronetics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neuronetics share price forecast for 2025?
The analyst consensus target price for shares in Neuronetics is $6.83. That is 52.46% above the last closing price of $4.48.
Analysts covering Neuronetics currently have a consensus Earnings Per Share (EPS) forecast of -$0.32 for the next financial year.
Find out moreWhat is the trend in the Neuronetics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuronetics. Over the past six months, its share price has outperformed the S&P500 Index by +376.96%.
As of the last closing price of $4.48, shares in Neuronetics were trading +109.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neuronetics PE Ratio?
The Neuronetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neuronetics?
Neuronetics' management team is headed by:
- Keith Sullivan - PRE
- Stephen Furlong - CFO
- W. Andrew Macan - SVP
- Cory Anderson - VPR
- Todd Cushman - VBD
- John Bakewell - IND
- Robert Cascella - IND
- Sheryl Conley - IND
- Wilfred Jaeger - IND
- Glenn Muir - IND
- Megan Rosengarten - IND
- Bruce Shook - IND